Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCN-01 + Durvalumab in Recurrent/Metastatic SCCHN
NCT03799744Phase 1Unknown
- Sponsor
- Institut Català d'Oncologia
- Start
- Mar 2019
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of zabilugene almadenorepvec in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Institut Català d'Oncologia. Primary endpoints: Safety by means of Adverse Events and Recommended Phase II Dose. Status: unknown.
02
Drugs
zabilugene almadenorepvec
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03799744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799744.